Current Funding Opportunity
Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
01/26/2022 03:56 PM EST
This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers.
The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.
Michael Krause, PhD | PAR-22-078
01/21/2022 07:02 PM EST
The impact of pain on patient quality of life for diseases and conditions within the mission of the NIDDK is enormous. Despite prior research efforts, our understanding of the underlying biological and clinical contributors of pain remains limited. In addition, new clinical management strategies that better measure, predict, and target pain and improve upon current interventions, such as opioids, are critically needed. The current Funding Opportunity Announcement will address these needs through solicitation of broad investigator-initiated research projects proposing novel basic, translational, and clinical studies and efforts to develop new approaches to assess and treat pain for disorders within the NIDDK’s mission. Investigations are expected to provide important new insights into the pathophysiology and clinical features of pain and foster new and improved treatment and pain management strategies for patients.
Chris Mullins, Ph.D.; Dana K. Andersen, M.D.; Teresa Jones, M.D. | RFA-DK-22-005
Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
01/20/2022 11:02 PM EST
NCATS is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of the Opioid Crisis as renewed in Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of the Opioid Crisis.
The Helping End Addiction Long-Term (HEAL) New Innovator Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research related to pain, opioid use disorder (OUD), and/or overdose (OD). Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged.
Dana K. Andersen, M.D. | RFA-TR-22-013
View All Funding Opportunities